Clinical Trial Update: Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant [NA]

View source ↗

Summary

A completed clinical trial evaluated Thymoglobulin to prevent acute graft-versus-host disease in patients with acute myeloid leukemia or acute lymphoblastic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Graft-versus-host Disease

Drugs mentioned

• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | NA | Status: COMPLETED